Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · July 02, 2015

Dose Reductions of Bleomycin and Vincristine Do Not Affect Efficacy in Advanced Hodgkin's Lymphoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials
J. Clin. Oncol 2015 Jun 22;[EPub Ahead of Print], H Haverkamp, B Böll, DA Eichenauer, S Sasse, M Fuchs, P Borchmann, V Diehl, A Engert, B von Tresckow

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading